Zobrazeno 1 - 10
of 16
pro vyhledávání: '"James Mitroka"'
Autor:
Suresh Yeola, Suzanne Wehrli, Keavy Daniel J, Craig Polson, Vikram Roongta, Ming Zheng, James Mitroka, Charles P. Sloan, Donglu Zhang, Qi Gao, Douglas D. Dischino, Ronald L. Hanson
Publikováno v:
Current Drug Metabolism. 7:883-896
BMS-299897 is a gamma-secretase inhibitor that has the potential for treatment of Alzheimer's disease. The metabolism of [(14)C]BMS-299897 was investigated in human liver microsomes, in rat, dog, monkey and human hepatocytes and in bile duct cannulat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a683d165023a181672b5f21dd531a66
https://doi.org/10.2174/138920006779010566
https://doi.org/10.2174/138920006779010566
Autor:
Samuel M. Cohen, James Mitroka, Martin Cano, Mark A. Dominick, M. Randy White, C. Robbie Waites, Lora L. Arnold, Terry Van Vleet, Thomas P. Sanderson, Beth E. Schilling
Publikováno v:
Toxicological Sciences. 96:58-71
Muraglitazar, a PPARa/g dual agonist, was dosed orally to rats once daily for 13 weeks to evaluate urinary and urothelial changes of potential relevance to urinary bladder tumorigenesis. Groups of 17 young or aged rats per sex were fed a normal or 1%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e537d87061d08b00aeab171e37a4f68
https://doi.org/10.1093/toxsci/kfl176
https://doi.org/10.1093/toxsci/kfl176
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 39:233-245
TopCount, a microplate scintillation counter (MSC), has been recently employed as an off-line liquid radiochromatographic detector for radioactive metabolite profile analysis. The present study was undertaken to validate TopCount for metabolite profi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63b3c6242dc71747dcf1de6df28a5539
https://doi.org/10.1016/j.jpba.2005.03.012
https://doi.org/10.1016/j.jpba.2005.03.012
Autor:
Mingshe Zhu, James Mitroka, Donglu Zhang, Weiping Zhao, Humberto Jimenez, Nimish Vachharajani, Suresh Yeola, Renke Dai
Publikováno v:
Drug Metabolism and Disposition. 33:500-507
This study was carried out to determine the metabolic pathways of buspirone and cytochrome P450 (P450) isoform(s) responsible for buspirone metabolism in human liver microsomes (HLMs). Buspirone mainly underwent N-dealkylation to 1-pyrimidinylpiperaz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b49ca97021a8279cee8bf58d3486334
https://doi.org/10.1124/dmd.104.000836
https://doi.org/10.1124/dmd.104.000836
Autor:
Terry R, Van Vleet, M Randy, White, Thomas P, Sanderson, Samuel M, Cohen, Martin, Cano, Lora L, Arnold, C Robbie, Waites, Beth E, Schilling, James, Mitroka, Mark A, Dominick
Publikováno v:
Toxicological sciences : an official journal of the Society of Toxicology. 96(1)
Muraglitazar, a PPARalpha/gamma dual agonist, was dosed orally to rats once daily for 13 weeks to evaluate urinary and urothelial changes of potential relevance to urinary bladder tumorigenesis. Groups of 17 young or aged rats per sex were fed a norm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::741b2819357622e5d66328c59bb286c1
https://pubmed.ncbi.nlm.nih.gov/17132713
https://pubmed.ncbi.nlm.nih.gov/17132713
Autor:
Suresh Yeola, Samuel J. Bonacorsi, Haiying Zhang, Nirmala Raghavan, Lifei Wang, Gamini Chandrasena, Litao Zhang, Vinayak Hosagrahara, Mingshe Zhu, Peter T. W. Cheng, Ming Yao, Donglu Zhang, Wenying Li, W. Griffith Humphreys, James Mitroka, Narayanan Hariharan, Wen Chyi Shyu
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 35(1)
Muraglitazar (Pargluva), a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) activator, has both glucose- and lipid-lowering effects in animal models and in patients with diabetes. This study describes the in vivo and in vitro compar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe2f448502ffb0359cd50c9ee4b96a22
https://pubmed.ncbi.nlm.nih.gov/17062777
https://pubmed.ncbi.nlm.nih.gov/17062777
Autor:
Mohammed Jemal, Samuel J. Bonacorsi, James Mitroka, J. Kent Rinehart, Sanaullah Khan, Jill C. M. Wait, Nimish Vaccharajani, Ramaswamy A. Iyer
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 34(6)
This study describes the pharmacokinetic parameters of gemopatrilat, a potent vasopeptidase inhibitor, in humans and the comparative biotransformation of the compound in rats, dogs, and humans after administration of a single oral dose of [14C]gemopa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f53a2fbc580b0114f46a3ec938a576cb
https://pubmed.ncbi.nlm.nih.gov/16540589
https://pubmed.ncbi.nlm.nih.gov/16540589
Autor:
Lewis J. Klunk, Donglu Zhang, Renke Dai, Lifei Wang, Narayanan Narasimhan, James Mitroka, Nuggehally R. Srinivas, Richard A. Reeves, Jianing Zeng, Rajesh Krishna
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 33(1)
MaxiPost [(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indole-2-one); BMS-204352] is an investigational maxi-K channel opener to treat ischemic stroke. This study reports the disposition, metabolism, pharmacokinetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bc4409f8ff6fd4876c1bce5153539f9
https://pubmed.ncbi.nlm.nih.gov/15502007
https://pubmed.ncbi.nlm.nih.gov/15502007
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 32(5)
MaxiPost [(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indole-2-one), or BMS-204352)] is a potent and specific maxi-K channel opener for potential use to treat stroke. This article describes structural characterizat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::162cfeaee30b44e069fc4f69359252de
https://pubmed.ncbi.nlm.nih.gov/15100177
https://pubmed.ncbi.nlm.nih.gov/15100177
Autor:
James Mitroka, Donglu Zhang, Renke Dai, Lewis J. Klunk, Vikram Roongta, Richard Gedamke, J. Kent Rinehart, Marc Ogan, Mingshe Zhu
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 31(7)
(3S)-(+)-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indole-2-one) (MaxiPost, BMS-204352) is a potent and specific opener for maxi-K channels and has potential to prevent and treat ischemic stroke. Following single intraven
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2855d8a581a78fad73ea93ec4d50cdc
https://pubmed.ncbi.nlm.nih.gov/12814959
https://pubmed.ncbi.nlm.nih.gov/12814959